adm glp 1 As of June 30, more than 8% of all US prescriptions were for GLP-1s, according to the latest GLP-1 monitoring report from Truveta Research. Prescriptions for GLP-1s have increased 5.6% since our Ideal for those on prescription GLP GLP-1 Meal Replacement Market Outlook

S., Viegas, R

Carpenter K

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 digital issues and online access to articles 135,68 per year only 11,31 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout References NCD Risk Factor Collaboration

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial